tbuckley/cabot-search huggingface dataset:
Argon plasma coagulation performed as a treatment for restenosis after placement of two duodenal self-expandable metallic stents
Authors: Akihisa Ohno, Toyoma Kaku, Masayuki Hijioka, Naohiko Harada, Makoto Nakamuta, Ken Kawabe
Journal: Endoscopy (2020)

Malignant gastroduodenal outlet obstruction (MGOO) is occasionally seen in patients with advanced pancreatic cancer. The endoscopic placement of self-expandable metallic stents (SEMS) has proven to be an effective treatment for MGOO [1] [2]. However, the optimal treatment for MGOO that recurs after the placement of a duodenal SEMS remains unknown. Although a few reports have shown argon plasma coagulation (APC) to be effective for treating stenosis of metallic esophagogastric stents [3] [4] [5], the application of APC to malfunction of a duodenal SEMS has not yet been reported. Hence, we are the first to report the case of a patient who underwent APC for recurrent MGOO after placement of two duodenal SEMS.
343P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety preliminary results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
Authors: T. de La Motte Rouge, J-S. Frenel, N. Isambert, G. Emile, C. Cropet, F. Legrand, A. Gonçalves
Journal: Annals of Oncology (2020)
Mapping the 17q12–21.1 Locus for Variants Associated with Early-Onset Asthma in African Americans
Authors: Hongsheng Gui, Albert M. Levin, Donglei Hu, Patrick Sleiman, Shujie Xiao, Angel C. Y. Mak, Mao Yang, Andrea J. Barczak, Scott Huntsman, Celeste Eng, Samantha Hochstadt, Ellen Zhang, Kyle Whitehouse, Samantha Simons, Whitney Cabral, Sami Takriti, Gonçalo Abecasis, Thomas W. Blackwell, Hyun Min Kang, Deborah A. Nickerson, Soren Germer, David E. Lanfear, Frank Gilliland, W. James Gauderman, Rajesh Kumar, David J. Erle, Fernando D. Martinez, Hakon Hakonarson, Esteban G. Burchard, L. Keoki Williams
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

The 17q12-21.1 locus is one of the most highly replicated genetic associations with asthma. Individuals of African descent have lower linkage disequilibrium in this region, which could facilitate identifying causal variants.
1896MO Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
Authors: D.C.C. Christoph, F. Barbato, M-K. Chodyla, W.P. Fendler, L. Kessler, K.L. Pomykala, M. Metzenmacher, F. Krefting, T. Hager, K. Herrmann, J. Ferdinandus
Journal: Annals of Oncology (2020)
643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT &amp; Tc99 scans
Authors: S. Gandhy, E.M. Gonzales, F. Karzai, J. Marte, M. Bilusic, S. McMahon, J. Strauss, S. Steinberg, A. Gill, A. Tubbs, J. Schonhoft, P. Choyke, B. Turkbey, L. Lindenberg, W.D. Figg, P. Arlen, W. Dahut, J.L. Gulley, R.A. Madan
Journal: Annals of Oncology (2020)
173P Prognostic impact of progesterone receptor levels in luminal-like Her2- early breast cancer patients: A retrospective analysis
Authors: F. Carlino, A. Diana, G. Buono, G. Arpino, E. Franzese, O. Oikonomidou, V. Famiglietti, G. Signoriello, F. De Vita, F. Ciardiello, M. Orditura
Journal: Annals of Oncology (2020)
1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Authors: M. Millward, S. Frentzas, H.K. Gan, A. Prawira, B. Tran, J. Coward, X. Jin, B. Li, M. Wang, K.Y. Kwek, Y. Xia, J. Desai
Journal: Annals of Oncology (2020)
Large prolapse-related lesions of the sigmoid colon
Authors: W. Arnout van Hattem, Neal Shahidi, Sergei Vosko, Iddo Bar-Yishay, Scott Schoeman, Mayenaaz Sidhu, Duncan McLeod, Michael J. Bourke
Journal: Endoscopy (2020)

Abstract Background Large prolapse-related lesions (LPRL) of the sigmoid colon have been documented histologically but may not be readily recognized endoscopically. Methods Colonic lesions referred for endoscopic mucosal resection (EMR) were enrolled prospectively. Endoscopic features were carefully documented prior to resection. Final diagnosis was made based on established histologic criteria, including vascular congestion, hemosiderin deposition, fibromuscular hyperplasia, and crypt distortion. Results Of 134 large ( ≥ 20 mm) sigmoid lesions, 12 (9.0 %) had histologic features consistent with mucosal prolapse. Distinct endoscopic features were: broad-based morphology; vascular pattern obscured by dusky hyperemia; blurred crypts of varying size and shape; and irregular spacing of sparse crypts. Focal histologic dysplasia was identified in 6 of 12 lesions (50.0 %). Conclusions LPRL of the sigmoid colon exhibit a distinct endoscopic profile. Although generally non-neoplastic, dysplasia may be present, warranting consideration of EMR.
TBC1D15/RAB7-regulated mitochondria-lysosome interaction confers cardioprotection against acute myocardial infarction-induced cardiac injury
Authors: Wenjun Yu, Shiqun Sun, Haixia Xu, Congye Li, Jun Ren, Yingmei Zhang
Journal: Theranostics (2020)

Rationale: Ischemic heart disease remains a primary threat to human health, while its precise etiopathogenesis is still unclear. TBC domain family member 15 (TBC1D15) is a RAB7 GTPase-activating protein participating in the regulation of mitochondrial dynamics. This study was designed to explore the role of TBC1D15 in acute myocardial infarction (MI)-induced cardiac injury and the possible mechanism(s) involved. Methods: Mitochondria-lysosome interaction was evaluated using transmission electron microscopy and live cell time-lapse imaging. Mitophagy flux was measured by fluorescence and western blotting. Adult mice were transfected with adenoviral TBC1D15 through intra-myocardium injection prior to a 3-day MI procedure. Cardiac morphology and function were evaluated at the levels of whole-heart, cardiomyocytes, intracellular organelles and cell signaling transduction. Results: Our results revealed downregulated level of TBC1D15, reduced systolic function, overt infarct area and myocardial interstitial fibrosis, elevated cardiomyocyte apoptosis and mitochondrial damage 3 days after MI. Overexpression of TBC1D15 restored cardiac systolic function, alleviated infarct area and myocardial interstitial fibrosis, reduced cardiomyocyte apoptosis and mitochondrial damage although TBC1D15 itself did not exert any myocardial effect in the absence of MI. Further examination revealed that 3-day MI-induced accumulation of damaged mitochondria was associated with blockade of mitochondrial clearance because of enlarged defective lysosomes and subsequent interrupted mitophagy flux, which were attenuated by TBC1D15 overexpression. Mechanistic studies showed that 3-day MI provoked abnormal mitochondria-lysosome contacts, leading to lysosomal enlargement and subsequently disabled lysosomal clearance of damaged mitochondria. TBC1D15 loosened the abnormal mitochondria-lysosome contacts through both the Fis1 binding and the RAB7 GAPase-activating domain of TBC1D15, as TBC1D15-dependent beneficial responses were reversed by interference with either of these two domains both in vitro and in vivo. Conclusions: Our findings indicated a pivotal role of TBC1D15 in acute MI-induced cardiac anomalies through Fis1/RAB7 regulated mitochondria-lysosome contacts and subsequent lysosome-dependent mitophagy flux activation, which may provide a new target in the clinical treatment of acute MI.
917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
Authors: C. Even, A. Daste, J. Fayette, G. Lefebvre, E. Saada-Bouzid, S. Zanetta, C. Toullec, D. Cupissol, S. Salas, M.C. Kaminski, A.C. Johnson, E. Vauleon, C. Le Tourneau, C. Sire, A. Prevost, I. Jallut, J. Bourhis, J. Guigay, A. Aupérin, M. Texier
Journal: Annals of Oncology (2020)
1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Authors: G.K. Abou-Alfa, I. Borbath, A.L. Cohn, L. Goyal, A. Lamarca, T. Macarulla, D-Y. Oh, S. Roychowdhury, S. Sadeghi, R.T. Shroff, M. Howland, A. Li, T. Cho, A. Pande, M. Javle
Journal: Annals of Oncology (2020)
93P IRF4 gene promoter methylation predicts efficacy of luminal B breast tumours neoadjuvant chemotherapy
Authors: V. Sigin, A.I. Kalinkin, N.V. Litviakov, E. Kuznetsova, O. Simonova, I. Volodin, E. Slonimskaya, M. Tsyganov, I.I. Vinogradov, M. Vinogradov, I.Y. Vinogradov, D.V. Zaletaev, V.V. Strelnikov, A.S. Tanas
Journal: Annals of Oncology (2020)
661P Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US
Authors: N. Shore, F. Laliberté, R. Ionescu-Ittu, A. Gayle, S. Amin, L. Yang, S. Payne, M. Mahendran, D. Lejeune, L. Yu, J. Burgents, M.S. Duh, S. Ghate
Journal: Annals of Oncology (2020)
1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
Authors: H. Verdaguer, M. Guardiola, F.M. Mancuso, D.A. Acosta Eyzaguirre, E. Buxò, J. Hernando, M. Diez Garcia, B. Laquente, I. Baraibar Argota, F.J. Ros Montañá, A. Garcia-Alvarez, J. Matito, A. Martin, A. Sierra, G. Villacampa Javierre, C. Molero, J.M. Miquel, A. Vivancos, R. Dienstmann, T. Macarulla Mercadé
Journal: Annals of Oncology (2020)
ERCP in patients with COVID-19 infection – is a single-use duodenoscope the safer option?
Authors: Mohammad Bilal, Tyler M. Berzin, Jonah Cohen, Mandeep S. Sawhney, Douglas K. Pleskow
Journal: Endoscopy (2020)

Letter to: Suggestions for infection prevention and control in digestive endoscopy during current 2019-nCoV pneumonia outbreak in Wuhan, Hubei province, ChinaEndoscopy 2020; 52(04): 312-314DOI: 10.1055/a-1128-4313 See also: ERCP during the COVID-19 epidemicEndoscopy 2020; 52(10): 933-934DOI: 10.1055/a-1194-4745
740P Response assessment in advanced renal cell carcinoma (mRCC) patients (pts) treated by Nivolumab (N) + Ipilimumab (I): CT volumetric measurement versus RECIST 1.1 response criteria
Authors: Q. Minault, P. Barthélémy, P. Leyendecker, M. Mielcarek, C. Roy
Journal: Annals of Oncology (2020)
658P Impact of a mutation in HSD3B1 gene on the effectiveness of androgenic deprivation treatment in prostate cancer
Authors: C.M. Martín-Abreu, R. Ramos-Díaz, I. Mourani-Padrón, B. Del Rosario-García, R.D. García-Marrero, A.C. Plata-Bello, G.J. Nazco-Casariego, F. Gutiérrez-Nicolás
Journal: Annals of Oncology (2020)
571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)
Authors: D. Zboralski, F. Osterkamp, A.D. Simmons, A. Bredenbeck, A. Schumann, M. Paschke, N. Beindorff, A-M. Mohan, M. Nguyen, J. Xiao, T.C. Harding, A. Hoehne, U. Reineke, C. Smerling
Journal: Annals of Oncology (2020)
1374P Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence
Authors: D.C.C. Christoph, F. Rizzo, K-O. Kambartel, S. Winke, J. Panse, D.S. Abdulla, M. Scheffler, I.T. Azeh, M. Hoiczyk, A. Turki, M. Metzenmacher
Journal: Annals of Oncology (2020)
203P Comparison of two pathologic response evaluation classification after neoadjuvant chemotherapy in patients with breast cancer
Authors: J. Ponce, A. Rodriguez-Lescure, G. Peiró, F. Aranda, M. Niveiro, Y.G. Montoyo-Pujol, M. Garcia-Escolano, S. Delgado, H. Ballester, T. Martín, I. Lozano, B. Massuti Sureda
Journal: Annals of Oncology (2020)
215P Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification
Authors: R.A. Escala Cornejo, M. Muñoz García, A. Olivares Hernández, M. Sancho de Salas, M.A. Gómez muñoz, J. Claros Ampuero, L. Figuero Pérez, E. Escalera Martín, B. Barrios Collado, G. Martín García, R. Seijas-Tamayo, A. Gómez Bernal, J.J. Cruz Hernández, C.A. Rodríguez Sánchez
Journal: Annals of Oncology (2020)
Notes from the Field: Travel-Associated Measles in a Person Born Before 1957 — Pinellas County, Florida, 2019
Authors: Kevin M. Baker, Abdiel E. Laureano-Rosario, Sharlene Edwards
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Measles is a highly contagious respiratory disease; both locally acquired and travel-associated cases continue to occur across the United States (1).On April 19, 2019, the Pinellas County (Florida) Health Department (Pinellas CHD) Epidemiology Program was notified by a local hospital of a case of serologically confirmed measles in a man aged 72 years.The patient was evaluated in a hospital emergency department (ED) on April 15 with a 5-day history of fever, followed 2 days later by cough, and a maculopapular rash that started on his trunk on April 15.In the ED the patient experienced difficulty breathing and was admitted.In the hospital he received a diagnosis of pneumonia and subsequently developed sepsis and was transferred to the intensive care unit.Measles immunoglobulin (Ig) M and IgG were detected at commercial laboratories on April 15 and April 19, respectively.The patient's wife reported that on April 12, she and her husband had returned from a month-long, multicountry trip to Asia.Their return trip included three flights on April 12, two of which landed at U.S. airports.After arriving home from the airport, the patient did not leave his house until seeking medical care at the ED on April 15.The patient's wife reported that he had measles as a child, and therefore, had not been vaccinated against measles; however, no documentation was available to support that her husband had a childhood measles infection.Urine and nasopharyngeal swab specimens were collected on April 19 for measles polymerase chain reaction testing at the Florida Department of Health, Bureau of Public Health Laboratories; both specimens tested positive.After measles was diagnosed on April 19, the Florida Department of Health notified the CDC Miami Quarantine Station that the patient had flown during his infectious period.CDC identified 31 exposed contacts on the inbound international flight and the domestic flight and notified three countries and four U.S. state health departments for follow-up.No secondary cases associated with the flights were identified.CDC also notified the destination country of the third flight.The patient's exposed close, personal contacts included his wife, his mother-in-law, and a friend; all were born before 1957 or had documented evidence of immunization or prior disease.While the patient was in the hospital ED, 432 other patients, visitors, and staff members were exposed.Line lists of patients, staff members, and other documented visitors * http://www.floridahealth.gov/diseases-and-conditions/disease-reporting-and-
1058P A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)
Authors: G. Zhang, Y. Hu, B. Yang, Q. Xu, J. Li, S. Sun, J. Zhang, S. Jiao
Journal: Annals of Oncology (2020)
1493P An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models
Authors: V. Gambardella, F. Gimeno-Valiente, M. Cabeza, F. Papaccio, S. Zúñiga-Trejos, J.A. Carbonell-Asins, P. Rentero-Garrido, M. Huerta, S. Roselló Keränen, J.M. Cejalvo, D. Roda, N. Tarazona, T. Fleitas, A. Cervantes, J. Castillo
Journal: Annals of Oncology (2020)
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Authors: S-E. Al-Batran, G.M. Haag, T.J. Ettrich, K. Borchert, A. Kretzschmar, C. Teschendorf, G.M. Siegler, M. Ebert, E. Goekkurt, M.K. Welslau, R.J.C. Mahlberg, N. Homann, D. Pink, W.O. Bechstein, P. Reichardt, T. Gaiser, D. Sookthai, C. Pauligk, T.O. Goetze, R.D. Hofheinz
Journal: Annals of Oncology (2020)
Correction: Focal Adhesion Kinase Targeting Using <i>In vivo</i> Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy
Authors: Jyotsnabaran Halder, Aparna A. Kamat, Charles N. Landen, Liz Y. Han, Susan K. Lutgendorf, Yvonne G. Lin, William M. Merritt, Nicholas B. Jennings, Arturo Chavez-Reyes, Robert L. Coleman, David M. Gershenson, Rosemarie Schmandt, Steven W. Cole, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Clinical Cancer Research (2019)

In the original version of this article (1), Fig. 4B included an incorrect IHC panel for CD31 with FAK siRNA + docetaxel. The error has been corrected in the latest online PDF version of the article. The authors regret this error.
948P Pre-treatment characteristics and long-term outcomes of recurrent-metastatic head and neck cancer patients treated with immune checkpoint inhibitors
Authors: M. Issa, T. Schultz, M. Xu, P. Bhateja, V. Karivedu, K. Dibs, M. Old, S. Kang, M. Gamez, J. Grecula, S. Jhawar, D. Mitchell, N. Seim, A. Agrawal, E. Ozer, S.S.B.E. Baliga, R. Carrau, J. Rocco, D. Blakaj, M. Bonomi
Journal: Annals of Oncology (2020)
409P Causes of mortality in elderly UICC stage III colon cancer (CC) patients (pts.) - Tumor related death and competing risks from the Colopredict Plus (CPP) registry
Authors: S. Nöpel-Dünnebacke, R. Klaassen-Mielke, I.S. Feder, A-L. Kraeft, C. Teschendorf, D. Collette, H. Böhner, L. Engel, L. Müller, F. Hartmann, U. Kaiser, H-R. Bruch, A. Giagounidis, U. Graeven, S. Hollerbach, D. Arnold, N. Timmesfeld, A. Reinacher-Schick, A. Tannapfel
Journal: Annals of Oncology (2020)
744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
Authors: P. Grivas, A.V. Balar, J. Vuky, R. de Wit, N.J. Vogelzang, T.K. Choueiri, D. Bajorin, D. Castellano Gauna, W. Gerritsen, H. Gurney, D.I. Quinn, S. Culine, Y. Fradet, A. Saadatpour, A. Loboda, J. Ma, M. Rajasagi, J.L. Godwin, B.H. Moreno, J. Bellmunt
Journal: Annals of Oncology (2020)
Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality
Authors: Vinay Sundaram, Rajiv Jalan, Parth Shah, Ashwani K. Singal, Arpan A Patel, Tiffany Wu, Mazen Noureddin, Nadim Mahmud, Robert J. Wong
Journal: Hepatology (2020)

We assessed the burden of nonalcoholic fatty liver disease (NAFLD)-related acute on chronic liver failure (ACLF) among transplant candidates in the United States, along with waitlist outcomes for this population.We analyzed the United Network for Organ Sharing registry from 2005 to 2017. Patients with ACLF were identified using the European Association for the Study of the Liver/Chronic Liver Failure criteria and categorized into NAFLD, alcohol-associated liver disease (ALD), and hepatitis C virus (HCV) infection. We used linear regression and Chow's test to determine significance in trends and evaluated waitlist outcomes using Fine and Gray's competing risks regression and Cox proportional hazards regression. Between 2005 and 2017, waitlist registrants for NAFLD-ACLF rose by 331.6% from 134 to 574 candidates (P < 0.001), representing the largest percentage increase in the study population. ALD-ACLF also increased by 206.3% (348-1,066 registrants; P < 0.001), whereas HCV-ACLF declined by 45.2% (P < 0.001). As of 2017, the NAFLD-ACLF population consisted primarily of persons aged ≥60 years (54.1%), and linear regression demonstrated a significant rise in the proportion of patients aged ≥65 in this group (β = 0.90; P = 0.011). Since 2014, NAFLD-ACLF grade 1 was associated with a greater risk of waitlist mortality relative to ALD-ACLF (subhazard ratio [SHR] = 1.24; 95% confidence interval [CI], 1.05-1.44) and HCV-ACLF (SHR = 1.35; 95% CI, 1.08-1.71), among patients aged ≥60 years. Mortality was similar among the three groups for patients with ACLF grade 2 or 3.NAFLD is the fastest rising etiology of cirrhosis associated with ACLF among patients listed in the United States. As the NAFLD population continues to grow and age, patients with NAFLD-ACLF will likely have the highest risk of waitlist mortality.
522TiP PRODIGE 71 - BEVAMAINT: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer
Authors: T. Aparicio, D. Malka, A. Turpin, E. Barbier, P. Laurent-Puig, A. Zaanan, D. Gonzalez, C. Choine, D. Tougeron, V. Hautefeuille, J.L. Legoux, C. Lepage, S. Manfredi
Journal: Annals of Oncology (2020)
977TiP Role of microbiome as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma 2 (ROMA LA-OPSCC2)
Authors: G.A. Watson, M. Oliva, B. Chen, A. Eliason, S. Jennings, R. Taylor, A.H. Abdalaty, A. Bayley, A. Hope, S. Bratman, D. Chepeha, I. Weinreb, J. Waldron, W. Xu, A.R. Hansen, L.L. Siu, B. Coburn, A. Spreafico
Journal: Annals of Oncology (2020)
1037P Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer
Authors: K. Cuppens, G. Froyen, B. Cruys, E. Geerdens, S. Zhang, B. Zhang, L. Decoster, M. Thomeer, B. Maes
Journal: Annals of Oncology (2020)
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
Authors: Youqiong Ye, Xinwei Kuang, Zuozhong Xie, Long Liang, Zhao Zhang, Yongchang Zhang, Fangyu Ma, Qian Gao, Ruimin Chang, Heng-Huan Lee, Shuang Zhao, Juan Su, Hui Li, Jingbo Peng, Huifang Chen, Minzhu Yin, Cong Peng, Nong Yang, Jing Wang, Jing Liu, Hong Liu, Leng Han, Xiang Chen
Journal: Genome Medicine (2020)

Abstract Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a small proportion of cancer patients. Recent studies have shown that matrix metalloproteinases (MMPs) are highly associated with the microenvironment of tumors and immune cells. However, it is unknown whether MMPs are involved in immunotherapy. Methods Here, we used integrative analysis to explore the expression landscape of the MMP family and its association with immune features across multiple cancer types. We used T cell cytotoxicity-mediated tumor killing assay to determine the co-cultured T cell activity of SB-3CT, an MMP2/9 inhibitor. We then used in vitro assays to examine the regulating roles of SB-3CT on PD-L1. We further characterized the efficacy of SB-3CT, in combination with anti-PD-1 and/or anti-CTLA4 treatment in mouse models with melanoma and lung cancer. Results Our computational analysis demonstrated a strong association between MMP2/9 and immune features. We demonstrated that inhibition of MMP2/9 by SB-3CT significantly reduced the tumor burden and improved survival time by promoting anti-tumor immunity. Mechanistically, we showed that SB-3CT treatment significantly diminished both mRNA and protein levels of PD-L1 in cancer cells. Pre-clinically, SB-3CT treatment enhanced the therapeutic efficacy of PD-1 or CTLA-4 blockade in the treatment of both primary and metastatic tumors. Conclusions Our study unraveled novel molecular mechanisms regarding the regulation of tumor PD-L1 and provided a novel combination therapeutic strategy of SB-3CT and ICB therapy to enhance the efficacy of immunotherapy.
153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer
Authors: V.E. Pacheco-Barcia, T. France, J. Asselah, R. Mondejar, G. Zogopoulos, R. Serrano, O. Donnay, J. Rogado, L. Del Campo, E. Martinez, E. Martin, C. Arlanzon, P. Ochoa, K. Guo, G. Barrena, R. Colomer Bosch
Journal: Annals of Oncology (2020)
1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience
Authors: W. Cui, C. Milner-Watts, I. Faull, R.J. Nagy, S. Scott, A. Minchom, J. Bhosle, N. Yousaf, M. O'Brien, S. Popat
Journal: Annals of Oncology (2020)